SLC43A2 and prostate cancer: In addition, L-leucine uptake by LNCaP cells, a LAT3 and LAT4-domionant prostate cancer cell line, was not altered by treatment of JPH203, even though the uptake was significantly decreased by treatment of BCH (29), indicating that JPH203 has a high specificity for the inhibition of LAT1 among system L. We demonstrated the significant decreasing in the pregabalin uptake by hCMEC/D3 cells in either case of the treatment of JPH203 and LAT1 siRNA (Table III and Fig. 3b).